Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pembrolizumab/vibostolimab - Merck Sharp & Dohme

Next Previous
Drug Profile

Pembrolizumab/vibostolimab - Merck Sharp & Dohme

Alternative Names: Coformulation pembrolizumab/vibostolimab - Merck Sharp & Dohme; MK-7684A; Pembrolizumab+vibostolimab; Vibostolimab+pembrolizumab; Vibostolimab/pembrolizumab - Merck Sharp & Dohme

Latest Information Update: 14 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Merck Sharp & Dohme
  • Class Antineoplastics; Antivirals; Immunotherapies; Monoclonal antibodies; Tumour-agnostic therapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death-1 receptor antagonists; T lymphocyte stimulants; TIGIT protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Malignant melanoma; Non-small cell lung cancer; Small cell lung cancer
  • Phase II Biliary cancer; Colorectal cancer; Endometrial cancer; Gallbladder cancer; Gastric cancer; Haematological malignancies; Head and neck cancer; Liver cancer; Oesophageal cancer; Ovarian cancer; Prostate cancer; Triple negative breast cancer; Uterine cancer
  • Phase I/II Bladder cancer
  • No development reported Solid tumours

Most Recent Events

  • 25 Jan 2024 Efficacy and adverse events data from a phase I/II trial in Prostate cancer presented at the 2024 Genitourinary Cancers Symposium (ASCO-GeCS-2024)
  • 07 Dec 2023 Updated efficacy and adverse events data from a phase II KeyVibe-002 trial in Non-small cell lung cancer presented at the European Society of Medical Oncology Annual Congress (ESMO-2023)
  • 31 May 2023 Phase-III clinical trials in Malignant melanoma (First-line therapy, In adolescents, In children, In the elderly, Late-stage disease, Adjuvant therapy, In adults) in Japan, USA, Argentina, Brazil, Chile, China, South Korea, New Zealand, Switzerland, Turkey (IV) (NCT05665595)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top